Orally treated patients always had a co-medication of LD and other PD drugs (typically entacapone, amantadine, or one of various dopamine agonists), whereas the dopaminergic medication only comprised LD in the LCIG group (with the exception of one patient who additionally took entacapone for COMT inhibition). Here, COMT is linked to Parkinson disease.